DeepMed Research

Abbisko Therapeutics Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Mass Balance Study of [14C]ABSK021

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Pimicotinib（ABSK021）

First Posted Date: 2024-01-02

Last Posted Date: 2024-08-12

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 6

Registration Number: NCT06186583

Locations: 🇨🇳
The First Affiliated Hospital of SOOCHOW UNIVERSITY, Suzhou, Jiangsu, China

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Phase 2

Conditions: cGvHD

Interventions: Drug: ABSK021

First Posted Date: 2024-01-02

Last Posted Date: 2024-08-12

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 64

Registration Number: NCT06186804

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

and more 11 locations

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Advanced Pancreatic Cancer

Interventions: Drug: Pimicotinib (ABSK021)

First Posted Date: 2023-11-01

Last Posted Date: 2024-04-11

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 82

Registration Number: NCT06111274

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Ha'erbin, China
🇨🇳
Shanghai East Hospital Tongji University, Shanghai, China
🇨🇳
Union Hospital Tongji Medical College Huazhong University of science and technolog, Wuhan, China

and more 2 locations

A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Part A ABSK201 and Itraconazole
Drug: Part A ABSK201 and Rifampicin

First Posted Date: 2023-10-18

Last Posted Date: 2024-08-12

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 32

Registration Number: NCT06089733

Locations: 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Phase 3

Active, not recruiting

Conditions: Pigmented Villonodular Synovitis
Giant Cell Tumor of Tendon Sheath
Tenosynovial Giant Cell Tumor

Interventions: Drug: Pimicotinib(ABSK021)
Drug: Placebo

First Posted Date: 2023-04-07

Last Posted Date: 2024-08-29

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 90

Registration Number: NCT05804045

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇵🇱
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

and more 37 locations

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Phase 2

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: AZD4547
Drug: Tislelizumab

First Posted Date: 2023-03-20

Last Posted Date: 2023-03-20

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 80

Registration Number: NCT05775874

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: ABSK121-NX

First Posted Date: 2022-11-25

Last Posted Date: 2024-08-09

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 169

Registration Number: NCT05627063

Locations: 🇨🇳
Mianyang Central Hospital, Mianyang, Sichuan, China
🇨🇳
The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States

and more 21 locations

ABSK091 Food Effect Study in Healthy Subjects

Phase 1

Completed

Conditions: Health, Subjective
Food-drug Interaction

Interventions: Drug: ABSK091 tablet

First Posted Date: 2022-09-09

Last Posted Date: 2022-09-09

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 13

Registration Number: NCT05533788

Locations: 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab in HCC Patients

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w

First Posted Date: 2022-07-01

Last Posted Date: 2022-09-26

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 62

Registration Number: NCT05441475

Locations: 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Hubei, Shanghai, China

ABSK021 Food Effect Study in Healthy Subjects

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: ABSK021 with fed state
Drug: ABSK021 with fasted state

First Posted Date: 2022-03-15

Last Posted Date: 2024-08-12

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 16

Registration Number: NCT05280483

Locations: 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy